Tests a method for tracking leftover multiple myeloma after transplant
Checks leftover myeloma cells in adults with multiple myeloma receiving maintenance therapy after transplant.
Plain-language title generated from the registry record
Registry title: Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Key facts
- Where
- Montreal, CanadaSee the site
Where in Canada
- Jewish General HospitalMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sir Mortimer B. Davis - Jewish General Hospital
- Trial code
- NCT05530096
- Record updated
- 3 April 2025
- Original description
The purpose :Read full original descriptionShow less
Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
The purpose :
Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Inclusion: Confirmed MM diagnosis; Transplant eligible patients in a first remission; Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed); Availability of deidentified patient's demographic and clinical follow up data; Receiving standard of care treatment; Able to provide informed consent.
Exclusion: Failure to meet inclusion criteria.